Educational guide
Amplifying the Future of Vaccine Development with saRNA
Time: RNA-based therapeutics continue to impress the scientific community with rapid production, speed-to-market, and efficacious results. While conventional mRNA strategies have paved the way for this groundbreaking technology, novel self-amplifying RNA (saRN
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
- Time:
RNA-based therapeutics continue to impress the scientific community with rapid production, speed-to-market, and efficacious results. While conventional mRNA strategies have paved the way for this groundbreaking technology, novel self-amplifying RNA (saRNA)-lipid nanoparticles (LNPs) are emerging as important therapeutic candidate molecules, especially as it pertains to vaccine development for various infectious diseases. For example, recent clinical trial data showed that an saRNA vaccine for COVID-19 was as effective as current mRNA vaccines but required a significantly lower dosage, resulting in therapeutic and manufacturing advantages. The formulation of saRNA therapeutics is similar to that of conventional mRNA, with innovative techniques employed to prepare the compounds for effective, targeted delivery.
In this GEN webinar, our distinguished speaker, Dr. Ethan Settembre, will introduce us to the intricacies of saRNA and how it elicits immune responses. Moreover, he will describe the differences between saRNA vs. mRNA, how saRNA can be applied to generate influenza and COVID-19 vaccines, and why it may represent the future of RNA therapeutic development.
A live Q&A followed the presentation, offering a chance to pose questions to our expert panelist.
Vice President, Head of Research Seqirus